High‐dose vs low‐dose colchicine
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review
- RR 2.11 [1.51, 2.95]1 study · 126 participantsLow
Findings
What do systematic reviews say?
15 questions · 16 findings · 9 reviews
No studies found 3 · 18.8%GRADE not reported 7 · 43.8%Very low 2 · 12.5%Low 3 · 18.8%Moderate 1 · 6.3%High 0 · 0%
High‐dose vs low‐dose colchicine
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
High‐dose vs low‐dose colchicine
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA)
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
- Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) 2012 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
High‐dose colchicine vs placebo
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 3.21 [2.01, 5.11]2 studies · 124 participantsLow
High‐dose colchicine vs placebo
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 111 participantsGRADE not reported
High‐dose colchicine vs placebo
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 111 participantsGRADE not reported
ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
- Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes onlyno estimate extracted1 participantsGRADE not reported
High‐dose corticosteroids vs moderate‐dose or no corticosteroids
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
- Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes onlyRR 8.02 [1.03, 62.37]2 studies · 77 participantsModerate
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin
Adverse events · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
High‐dose methylphenidate vs placebo
Total number of adverse events · Children aged 6 to 18 years with ASD
2 findings from 1 review
- Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 108 participantsGRADE not reported
- Methylphenidate for children and adolescents with autism spectrum disorder 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 79 participantsGRADE not reported
Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: high‐dose urate oxidase showed no clear difference in frequency of adverse events ( compared with low‐dose urate oxidase (low certainty).
1 finding from 1 review
- Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer 2017 · Cochrane Headline outcomes onlyRR 0.54 [0.12, 2.48]1 study · 29 participantsLow
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
- Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 1080 participantsVery low
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
- Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 98 participantsVery low